Fatima Zahra Bellefkih

Fatima Zahra Bellefkih

Auto-generated profile, based on publicly available information

Fatima Zahra Bellefkih

Department of Radiation Oncology and Henri Mondor Breast Center, Henri Mondor University Hospital, APHP, UPEC, Créteil, France

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2024 in Brachytherapy
Verified
Journal Article
Closed access
TCTarik Chekrine
Tarik Chekrine
FBFatima Zahra Bellefkih
Fatima Zahra Bellefkih
GHGhita Hatim
Ghita Hatim
ZBZineb Bouchbika
Zineb Bouchbika
NBNadia Benchakroun
Nadia Benchakroun
SSSouha Sahraoui
Souha Sahraoui

1 July 2026 in JCO Global Oncology
Verified
Journal Article
Closed access
KDKamel Debbi
Kamel Debbi
FBFatima Zahra Bellefkih
Fatima Zahra Bellefkih
ABAlexander Bbennassi
Alexander Bbennassi
MBMeriem El Bachiri
Meriem El Bachiri
SMSalma El Mouhtadi
Salma El Mouhtadi
YBYazid Belkacemi
Yazid Belkacemi
PURPOSE: The integration of novel systemic therapies including antibody-drug conjugates (ADCs), immune checkpoint inhibitors (ICIs), and cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors with radiotherapy (RT) presents new opportunities in breast cancer (BC) management. However, clinical guidance on concurrent administration remains limited, particularly for advanced techniques. MATERIALS AND METHODS: A multidisciplinary panel of radiation and medical oncologists from AROME and the Moroccan Medical Oncology Association conducted a literature review and established expert consensus recommendations during the fourth Moroccan Congress of Medical Oncology Private Practice. An evidence-informed, structured consensus process was used to achieve agreement on safety profiles across six RT modalities. RESULTS: Trastuzumab deruxtecan has shown a favorable safety profile with whole-breast irradiation and palliative RT, while trastuzumab emtansine combined with stereotactic radiosurgery shows elevated radionecrosis risk. ICIs are generally feasible with most RT modalities and toxicity monitoring applied; however, risk is context dependent, and evidence supporting stereotactic body radiotherapy-ICI benefit in oligometastatic BC remains limited. The use of CDK4/6 inhibitors concurrently with conventional and stereotactic RT seems feasible, although caution is advised for visceral metastases. These experts' agreements are supported by retrospective data and preclinical evidence, highlighting the need for prospective validation. CONCLUSION: This expert consensus statement provides pragmatic, modality-specific guidance on combining contemporary RT techniques with selected novel systemic agents in BC, complementing existing European Society for Medical Oncology /European Society for Radiotherapy and Oncology‑oriented frameworks and highlighting areas where prospective data are still needed. The findings underscore the importance of toxicity monitoring, particularly for ADCs in CNS-directed therapies, and call for biomarker-driven studies to optimize combination strategies. These recommendations aim to guide safe integration of novel agents with RT across resource-variable settings, including low- and middle-income countries.

25 May 2026 in Clinical and Translational Radiation Oncology
Verified
Journal Article
Open access
ABAlexander Bbennassi
Alexander Bbennassi
KDKamel Debbi
Kamel Debbi
NGNicolas Giraud
Nicolas Giraud
LBLahcene Belaidi
Lahcene Belaidi
ADAnna Durigova
Anna Durigova
YBYazid Belkacemi
Yazid Belkacemi
Bilateral adrenal metastases are rare but clinically significant. While stereotactic body radiotherapy (SBRT) provides excellent local control, the risk of post-treatment primary adrenal insufficiency (PAI) after bilateral irradiation remains poorly defined and lacks standardized management guidelines. We performed a comprehensive literature review following PRISMA principles, using PubMed and Embase databases (January 1956 to June 2025). Studies including patients with bilateral adrenal metastases treated with radiotherapy, or unilateral irradiation in the setting of a solitary adrenal gland, were eligible. Data on treatment characteristics, incidence of PAI, diagnostic approaches, and management were extracted. In parallel, a multidisciplinary expert panel developed expert opinion–based practical recommendations for the screening, treatment, and follow-up of PAI. Thirty studies comprising 156 patients treated with bilateral adrenal irradiation (or irradiation of a solitary adrenal gland) were included. PAI was reported in 47 patients (30%), although systematic endocrine evaluation was performed in only a minority of studies, suggesting potential underestimation. Time to onset ranged from 3 to 30 months. Reporting of diagnostic work-up, management, and follow-up was highly heterogeneous, and treatment details were frequently lacking. No study identified reliable dosimetric predictors of PAI, and no association between radiation dose parameters and adrenal insufficiency was demonstrated. PAI following bilateral adrenal radiotherapy is likely under-recognized and under-reported, with clinically meaningful incidence and potential life-threatening consequences. In the absence of robust data, systematic hormonal assessment, careful treatment planning, and structured long-term follow-up are essential. We propose practical, expert-based recommendations to guide clinical management, while emphasizing the need for prospective studies to better define incidence, risk factors, and optimal prevention strategies.